Related Experiment Video
Updated: Jul 3, 2026
08:01
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Current experimental therapy for Alzheimer's disease.
Sheng Chen1, Xiao-Jie Zhang, Liang Li
1Institutes of Neurology, Ruijin Hospital, Jiao Tong University School of Medicine, Shanghai, China.
Current Neuropharmacology
|July 11, 2008
Summary
Researchers are exploring new Alzheimer's disease (AD) therapies beyond traditional treatments. Current experimental approaches focus on targeting amyloid plaques and neurofibrillary tangles for potential future cures.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Alzheimer's disease (AD) research has significantly advanced in understanding its genetic and molecular basis over the last decade.
- Traditional treatments for AD, such as anti-acetylcholinesterase inhibitors, are being complemented by novel therapeutic strategies.
Purpose of the Study:
- This review synthesizes current experimental studies on Alzheimer's disease therapeutics.
- The focus is on novel approaches targeting the molecular pathogenesis of AD, including secretase-based drug development, immunotherapy, and anti-neurofibrillary tangle interventions.
Main Methods:
- The review covers experimental studies and therapeutic strategies currently under investigation.
- Key areas examined include targeting amyloid plaque formation and amyloid beta (Abeta)-mediated cytotoxicity.
- Interventions aimed at preventing neurofibrillary tangle generation are also discussed.
Main Results:
- Current research trends shift towards multi-targeted therapies for AD.
- Experimental approaches are exploring interventions against key pathological hallmarks of Alzheimer's disease.
- Significant progress is being made in developing novel therapeutic agents.
Conclusions:
- Emerging therapeutic strategies offer hope for reversing Alzheimer's disease progression.
- Future AD therapy is moving towards a multi-mechanistic approach.
- Ongoing research in secretase inhibition, immunotherapy, and tangle intervention may lead to a cure for Alzheimer's disease.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...